Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.37 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140210 | 0.82 | TSHR (0.36) | KDM4ELMNAMAPK1MAPTKCNQ3 | |
| SCHEMBL30853648 | 0.82 | TSHR (0.36) | KDM4ELMNAMAPK1MAPTKCNQ3 | |
| SCHEMBL11156490 | 0.80 | POLB (0.37) | KDM4ELMNAMAPK1MAPTHTT | |
| SCHEMBL23070510 | 0.79 | MMP8 (0.37) | KDM4ELMNAMAPK1HTTCYP1A2 | |
| SCHEMBL22964482 | 0.79 | MAPT (0.39) | KDM4ELMNAMAPK1MAPTCYP1A2 | |
| SCHEMBL11730443 | 0.76 | ALDH1A1 (0.41) | KDM4ELMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL142930 | 0.75 | THRB (0.44) | LMNAMAPTHTTCYP1A2CYP2C9 | |
| SCHEMBL2138531 | 0.75 | APP (0.48) | LMNAMAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25791893 | 0.74 | CA1 (0.51) | KDM4ELMNAMAPTCA1CA2 | |
| SCHEMBL11152796 | 0.74 | NPSR1 (0.46) | LMNAMAPTCYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242278-B2 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20120101278-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | HAGIYA KOJI (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-1473286-B1 | PROCESS FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-20090216017-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | HAGIYA KOJI | 2009-08-27 | — | — | US | disclosed |
| US-7554000-B2 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20050096471-A1 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-1473286-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2004-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101278-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | PPOX, CAT, TYR | KDM4E 3428/4885LMNA 3829/4885MAPK1 3469/4885 |
| US-20090216017-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | PPOX, CAT, TYR | KDM4E 3428/4885LMNA 3829/4885MAPK1 3469/4885 |
| US-20050096471-A1 | Process for producing biaryl compound | PPOX, CAT, TYR | KDM4E 3428/4885LMNA 3829/4885MAPK1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.